Table 3Overview of published literature (n=17 studiesa), with number of metastatic breast cancer patients (n=557)

Bone Scan (n=3 studies; 123 patients)MRI (n=4 studies; 130 patients)CT (n=7 studies; 206 patients)FDG-PET or FDG-PET/CT (n=10 studies; 454 patients)FLT-PET/CT (n=4 studies; 33 patients)F-FMISO PET/CT (n=1 study; 12 patients)FES-PET/CT (n=2 studies; 74 patients)Total (n=17 studies; 557 patients)
Study Population
 United States2
(n=76)
2
(n=61)
2
(n=76)
4
(n=279)
1
(n=14)
02
(n=74)
8
(n=273)
 Europe1
(n=47)
2
(n=69)
5
(n=130)
5
(n=163)
3
(n=19)
008
(n=272)
 Asia0001
(n=12)
01
(n=12)
01
(n=12)
Study Type
 Cohort (retrospective)2
(n=94)
1
(n=47)
2
(n=94)
6
(n=351)
002
(n=74)
7
(n=378)
 Cohort (prospective)1
(n=29)
3
(n=83)
5
(n=112)
4
(n=103)
4
(n=33)
1
(n=12)
010
(n=179)
 Randomized control trial00000000
Comparatorsb
 Tracer uptake vs. anatomic imaging2
(n=94)
3
(n=116)
6
(n=177)
4
(n=163)
3
(n=28)
01
(n=47)
7
(n=191)
 2 tracer uptakes0001
(n=12)
01
(n=12)
01
(n=12)
 Tracer uptake vs. biomarkers0002
(n=127)
2
(n=19)
004
(n=146)
 Bone scan vs. anatomic imaging1
(n=29)
01
(n=29)
00001
(n=29)
Outcomesc
 Tumor response3
(n=123)
3
(n=116)
7
(n=206)
10
(n=454)
4
(n=33)
1
(n=12)
2
(n=74)
16
(n=543)
 Progression-free survival1
(n=29)
01
(n=29)
3
(n=149)
0004
(n=178)
 Overall survival1
(n=76)
3
(n=83)
4
(n=145)
5
(n=240)
0005
(n=283)

CT = computed tomography; F-FMISO = F-fluoromisonidazole; FDG = fluorodeoxyglucose; FES = fluoroestradiol; FLT = fluorothymidine; MRI = magnetic resonance imaging; PET = positron emission tomography

a

Eight studies included greater than one type of imaging

b

Five studies did not include comparators of imaging

c

Some studies reported greater than one outcome

From: Findings

Cover of Imaging Techniques for Treatment Evaluation for Metastatic Breast Cancer
Imaging Techniques for Treatment Evaluation for Metastatic Breast Cancer [Internet].
Technical Briefs, No. 17.
Gold LS, Lee CI, Devine B, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.